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The NAD-dependent deacetylase SIRT1 regulates lipid and carbohydrate metabolism and has been
shown to extend life span in several species. In a recent issue ofMolecular Cell, Li et al. (2007) dem-
onstrate that SIRT1 deacetylates and activates the nuclear receptor LXR by favoring its ligand-
dependent proteasomal degradation, thereby potentially regulating reverse cholesterol transport.Sirtuins are NAD-dependent deacety-
lases that target histones, transcrip-
tion factors, and coregulators to adapt
gene expression to the cellular ener-
getic state (Yamamoto et al., 2007).
The founding member of the family,
SIRT1, promotes longevity in species
ranging from yeast to mammals, and
it is believed that these protective ac-
tions may result at least in part from
the beneficial regulation of energy and
metabolic homeostasis. Despite the
impact of high cholesterol levels on
mortality, cholesterol has not been
associated with the sirtuin gene family
until recently. The concentration of
cholesterol, a lipid that maintains cell
membrane structure and is a pre-
cursor for the synthesis of bile acids,
steroids, and vitamin D, is finely tuned.
When the cholesterol concentration
rises in the body, macrophages accu-
mulate cholesterol, favoring the de-
velopment of atherosclerosis, which
negatively affects life span. Excess
cholesterol can be removed from mac-
rophages by high-density lipoprotein
(HDL)-mediated reverse cholesterol
transport (RCT), which redirects cho-
lesterol to the liver for subsequent
elimination via the bile. RCT is con-
trolled by cholesterol transporters and
metabolizing enzymes, which are tran-
scriptionally regulated by the liver Xreceptors (LXRs) a and b, two nu-
clear receptors (NRs) that act as cho-
lesterol sensors (Zelcer and Tontonoz,
2006).
Li et al. (2007) now report that SIRT1
deacetylates and induces LXRa and
b activity. LXR is acetylated on lysine
432 (K432), located within helix 12 of
the ligand-binding domain, whose re-
positioning upon ligandbinding confers
transcriptional activation. Interestingly,
LXR agonists trigger deacetylation
of the receptor, a process in which
SIRT1 plays an important role, since it
interacts with LXR and its absence
blunts LXR deacetylation. However, it
isnot clear at present whetherSIRT1 in-
teracts with LXR in a ligand-dependent
manner or whether the ligand-depen-
dent deacetylation results from confor-
mational changes of the receptor. In
addition, further studies will be required
to identify the acetyltransferases that
promote LXR acetylation.
NRs associate with target pro-
moters and induce transcriptional
activation in a cyclical manner, which
requires rounds of NR ubiquitination
and proteasomal degradation (Reid
et al., 2003). Li et al. (2007) demon-
strate that LXR is hypo-ubiquitinated
and therefore stabilized in the absence
of SIRT1 and that mutation of K432
recapitulates this state, suggestingCell Metabolism 6,that acetylation of K432 prevents LXR
ubiquitination and its subsequent deg-
radation by the proteasome. Paradox-
ically, but as observed for other NRs,
LXR stabilization by inhibition of its
ubiquitination and proteasomal degra-
dation reduces its transcriptional ac-
tivity, explaining the lower LXR activity
observed in the absence of SIRT1 or
upon mutation of its target site K432.
Interestingly, it seems that it is the
availability of this key lysine residue
more than the acetyl moiety itself that
inhibits ubiquitination and limits LXR
action. Indeed, the mutation of K432
to either arginine or glutamine, which
mimic a constitutively deacetylated
and acetylated lysine, respectively, but
neither of which can be ubiquitinated,
inhibits LXR activity.
The regulation of LXR activity by
acetylation adds this NR to the grow-
ing list of transcriptional regulators
whose activity is regulated by acetyla-
tion. Acetylation has been reported
to regulate the activity of NRs such
as the glucocorticoid and androgen
receptors and steroidogenic factor 1
(SF-1/Ad4BP).SIRT1 also deacetylates
other transcription factors and coregu-
lators (Figure 1; Yamamotoet al., 2007),
and acetylation of transcription factors
synergizes or competes with other
posttranslational modifications suchNovember 2007 ª2007 Elsevier Inc. 343
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PreviewsFigure 1. SIRT1 Regulates Homeostatic Gene Expression Programs by Deacetylating Key Transcription Factors and Coregulators
SIRT1 is a nuclear class III deacetylase that transfers the acetyl group of an acetylated substrate to ADP-ribose. The activity of SIRT1 is allosterically
controlled by the levels of oxidized nicotinamide adenine dinucleotide (NAD+), which increase when energy supplies are low. SIRT1 is therefore a sen-
sor of energetic levels that regulates the activity of transcription factors and coregulators via deacetylation. The number of acetylated lysines and
the main biological consequences of SIRT1-mediated deacetylation are indicated. Abbreviations: LXR, liver X receptor; NCoR, nuclear receptor
corepressor; PPARg, peroxisome proliferator-activated receptor g; PGC-1a, PPARg coactivator 1a; FOXO, forkhead box O; P/CAF, P300/CBP-
associated factor; MyoD, myoblast determination protein 1; NF-kB, nuclear factor kB.as phosphorylation, SUMOylation, and
ubiquitination to regulate gene expres-
sion (Lonard and O’Malley, 2007).
From all of these studies, a general pic-
ture emerges wherein the combination
of distinct posttranslational modifica-
tions on many actors of a transcrip-
tional network determines the final
transcriptional output.
Li et al. (2007) also characterize the
consequences of the regulation of LXR
by SIRT1 on cholesterol homeostasis
by showing that Sirt1/ mice have
lower levels of HDL cholesterol, while
low-density lipoprotein (LDL) choles-
terol is unaffected. Since cholesterol
export is reduced in macrophages
and liver from Sirt1/ mice, it seems
that SIRT1 may positively control LXR
activity in vivo to stimulate RCT. Con-
sistent with this hypothesis, Sirt1/
mice accumulate hepatic cholesterol.
However, it is unclear whether this ac-
cumulation of cholesterol stems solely
from the inhibition of direct cholesterol
excretion in bile or whether the LXR-
dependent conversion of cholesterol
to bile acids, catalyzed by the enzyme
CYP7A1, is also inhibited. Although
SIRT1 has been shown to occupy the344 Cell Metabolism 6, November 2007 ªCyp7a1 promoter in cellular models,
thus suggesting that SIRT1 can pro-
mote bile acid synthesis, changes of
CYP7A1 expression or bile acid pool
were not investigated by Li et al.
Puigserver’s group, however, recently
showed that CYP7A1 expression is re-
duced in the absence of SIRT1, sug-
gesting that bile acid synthesis, in addi-
tion to macrophage cholesterol efflux,
is enhanced by SIRT1. Interestingly,
the regulation of CYP7A1 was also
found to be dependent on the coregu-
lator PGC-1a (Rodgers and Puigserver,
2007), but it remains unclear whether
the direct deacetylation of PGC-1a by
SIRT1 is involved (Rodgers et al., 2005).
The inhibition of RCT in SIRT1-defi-
cient mice suggests that the pharma-
cological modulation of SIRT1 could
be of interest to curb atherosclerosis.
However, it is currently unclear whether
this conclusion, based on loss-of-func-
tion studies in mice, will extend to con-
ditions of SIRT1 activation in humans,
which regulate cholesterol differently
from mice. Several studies in mice also
challenge this conclusion and suggest
that the actions of SIRT1 on cholesterol
homeostasis may be complex. Activa-2007 Elsevier Inc.tion of SIRT1 by resveratrol administra-
tion, for instance, does not impact
cholesterol levels (Baur et al., 2006;
Lagouge et al., 2006). Strikingly, cho-
lesterol levels are reduced both in
Sirt1/ mice and in mice overexpress-
ing SIRT1 (Li et al., 2007; Bordoneet al.,
2007). The fact that calorie restriction,
which is known to activate SIRT1,
improves atherosclerosis and choles-
terol homeostasis in humans, however,
agrees with the hypothesis of Li et al.
(Fontana et al., 2004). To address
the complex impact of the SIRT1-
mediated regulation of LXR and cho-
lesterol homeostasis, studies in mice
that are either challenged by a hyper-
cholesterolemic diet or genetically
predisposed to atherosclerosis will be
required. Furthermore, tissue-specific
contribution of SIRT1 to RCT will only
be elucidated by the future study of
mice with specific inactivation of SIRT1
in macrophages, liver, and intestine.
Activation of LXR is beneficial in that
it not only inhibits intestinal cholesterol
uptake and promotes RCT but also
exerts potent anti-inflammatory effects
that involve transrepression (Zelcer
and Tontonoz, 2006). It will therefore
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Previewsbe important to dissect to what extent
the SIRT1-mediated deacetylation of
LXR can affect these anti-inflamma-
tory effects. In that respect, it is worth
noting that transrepression by LXR re-
quires its SUMOylation (Ghisletti et al.,
2007), again underscoring the poten-
tial impact of various posttranslational
modifications on transcriptional re-
gulation. Finally, a major adverse ef-
fect of LXR activation is hepatic stea-
tosis as a consequence of lipogenesis
(Zelcer and Tontonoz, 2006). SIRT1-
mediated activation of LXR could here
have an edge over LXR ligands, since
SIRT1 agonists may limit hepatic lipid
accumulation because of the concom-
itant induction of oxidative metabolism
through AMPK and PGC-1a activation
(Baur et al., 2006; Lagouge et al., 2006).
Altogether, recent studies extend
the role of SIRT1 in metabolic homeo-
stasis to the regulation of cholesterolMore Than Satie
and Glucose Hom
Pavlos Pissios1 and Eleftheria Marat




Serotonergic agents have been
reported by Zhou et al. (2007) in
on peripheral glucose homeostas
Previous research on appetite sup-
pression by serotonin has centered
on the role of serotonin signaling in
the brain’s ‘‘appetite center,’’ the hy-
pothalamus. Effective weight loss has
been achieved via fenfluramine and
dexfenfluramine, which increase brain
serotonin by interfering with its uptake
and causing a reverse release of sero-
tonin through the serotonin trans-
porter. Of the many subtypes of sero-
tonin (5-HT) receptors, the 5-HT2C
receptor (5-HT2CR) is the proposed
target mediating the anorectic effectsmetabolism (Li et al., 2007; Rodgers
and Puigserver, 2007). Although fur-
ther studies will be required, these
results also suggest potential new
pharmacological strategies to combat
age-related diseases resulting from
hypercholesterolemia.
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2007). Most studies have focused on
the weight-reducing properties of sero-
tonergic agents; their role in peripheral
metabolism has not been previously ex-
plored. In this issue, Zhou et al. (2007)
show that subanorectic doses of
mCPP, a classical 5-HT2CR agonist,
also affect glucose homeostasis inde-
pendent of food intake and weight loss.
Zhou et al. (2007) present convinc-
ing evidence for improved glucose and
insulin tolerance in genetic and diet-
induced models of obesity after both
acute injections and long-term infusion
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